Cargando…

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis

INTRODUCTION: Network meta-analyses have confirmed that paclitaxel plus carboplatin could improve progression-free survival (PFS) and overall survival (OS) compared with platinum alone. However, detailed implementation schedule (weekly or 3-weekly therapy) was not specified in clinical practice guid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Weitao, Fu, Yu, Dang, Yun, Cai, Bingxin, Tuo, Shumei, Mao, Baohong, Lin, Ru, Liu, Qing, Li, Yilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928320/ https://www.ncbi.nlm.nih.gov/pubmed/35296476 http://dx.doi.org/10.1136/bmjopen-2021-053182

Ejemplares similares

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
por: Kim, Yoo-Na, et al.
Publicado: (2019)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
por: Lee, Matilda X., et al.
Publicado: (2018)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
por: Landry, Kara K, et al.
Publicado: (2022)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
por: Onaga, Ryutaro, et al.
Publicado: (2023)

Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study
por: Joseph, Deepa M., et al.
Publicado: (2021)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Severe skin toxicity due to weekly paclitaxel administration
por: Kate, Shruti, et al.
Publicado: (2015)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
por: Sharma, R, et al.
Publicado: (2009)

Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
por: Wang, Hai-ying, et al.
Publicado: (2016)

A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma
por: Xia, Yi, et al.
Publicado: (2018)

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients
por: de Man, Femke M., et al.
Publicado: (2019)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer
por: Sharma, Rohini, et al.
Publicado: (2011)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
por: Carinato, Hélène, et al.
Publicado: (2021)

Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study
por: van Meerten, E, et al.
Publicado: (2006)

Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule
por: Pêtre, Adeline, et al.
Publicado: (2018)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
por: Srinivasan, K. N, et al.
Publicado: (2014)

Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort
por: Pirolli, Rafaela, et al.
Publicado: (2021)

A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
por: Liu, Ke-Jun, et al.
Publicado: (2014)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
por: Mullany, Sally, et al.
Publicado: (2020)

3-Weekly Paclitaxel-Carboplatin With Radical Radiation for Stage III NSCLC – An Option During COVID-19 Pandemic
por: Wong, H.C.Y., et al.
Publicado: (2021)

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
por: Igawa, Satoshi, et al.
Publicado: (2018)

A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non–small-cell lung cancer
por: Hasegawa, Takaaki, et al.
Publicado: (2016)

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
por: Gong, Wenjian, et al.
Publicado: (2023)

Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2022)

Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial
por: Li, Li, et al.
Publicado: (2018)

The Effect of Neoadjuvant Chemotherapy Combined With Brachytherapy Before Radical Hysterectomy on Stage IB2 and IIA Cervical Cancer: A Retrospective Analysis
por: Dang, Yun, et al.
Publicado: (2021)

PO-1174 3-weekly paclitaxel-carboplatin with radiation for stage III NSCLC – option during COVID-19 pandemic
por: Wong, H., et al.
Publicado: (2021)

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8i5c1kb38evbgf52rs4fvu8a8q